Albert Bourla, the CEO of Pfizer, said a COVID-19 vaccine that specifically targets the Omicron variant of the virus as well as already circulating variants “will be ready in March.” “This vaccine will be ready in March. I don’t know how if we will need it, I don’t know how it will be used, but it will be ready, and in fact, we [are] already starting manufacturing some of these quantities at risk,” Bourla told CNBC on Monday. Separately, at J.P. Morgan’s annual health care conference, which is being held virtually, Bourla said Pfizer is ready to file for U.S. regulatory approval for the redesigned COVID-19 vaccine, and that the company has built up ample manufacturing capacity, such that it will not be a problem to switch immediately. COVID-19 vaccines eventually could be an annual shot for most people, Bourla said, and some high-risk groups might be eligible to receive the shots more …